Clinical Trial Update: The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) [Phase 2]

View source ↗

Summary

Phase 2 trial of gefapixant (MK-7264) in female participants with Bladder Pain Syndrome was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Pain Syndrome

Drugs mentioned

• AF-219
• Gefapixant (gefapixant)
• MK-7264 (MK-7264)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Bladder Pain Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2017-01-12